Prot. #EVP-6124-024: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase

Project: Research project

Project Details

StatusFinished
Effective start/end date3/10/143/10/17

Funding

  • inVentiv Health Clinical (EVP-6124-024 // EVP-6124-024)
  • FORUM Pharmaceuticals Inc. (EVP-6124-024 // EVP-6124-024)